Genetic basis of Cowden syndrome and its implications for clinical practice and risk management
Authors:
Open Access
- 1 July 2016
- journal article
- review article
- Published by Taylor & Francis in The Application of Clinical Genetics
- Vol. ume 9, 83-92
Abstract
Cowden syndrome (CS) is an often difficult to recognize hereditary cancer predisposition syndrome caused by mutations in phosphatase and tensin homolog deleted on chromosome 10 (PTEN). In addition to conferring increased cancer risks, CS also predisposes individuals to developing hamartomatous growths in many areas of the body. Due to the rarity of CS, estimates vary on the penetrance of certain phenotypic features, such as macrocephaly and skin findings (trichilemmomas, mucocutaneous papules), as well as the conferred lifetime cancer risks. To address this variability, separate clinical diagnostic criteria and PTEN testing guidelines have been created to assist clinicians in the diagnosis of CS. As knowledge of CS increases, making larger studies of affected patients possible, these criteria continue to be refined. Similarly, the management guidelines for cancer screening and risk reduction in patients with CS continue to be updated. This review will summarize the current literature on CS to assist clinicians in staying abreast of recent advances in CS knowledge, diagnostic approaches, and management.Keywords
This publication has 56 references indexed in Scilit:
- PTEN Germline Mutations in Patients Initially Tested for Other Hereditary Cancer Syndromes: Would Use of Risk Assessment Tools Reduce Genetic Testing?The Oncologist, 2013
- High cumulative risks of cancer in patients with PTEN hamartoma tumour syndromeJournal of Medical Genetics, 2013
- Should patients with Cowden syndrome undergo prophylactic thyroidectomy?Surgery, 2012
- A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 ProbandsThe American Journal of Human Genetics, 2011
- Beyond BRCA1 and BRCA2 wild‐type breast and/or ovarian cancer families: germline mutations in TP53 and PTENClinical Genetics, 2010
- Endometrial Cancer in an AdolescentObstetrics & Gynecology, 2009
- Cowden Syndrome: A Critical Review of the Clinical LiteratureJournal of Genetic Counseling, 2008
- Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with RapamycinCancer Research, 2008
- Evaluation of germline PTEN mutations in endometrial cancer patientsGynecologic Oncology, 2005
- Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomasNature Genetics, 2002